These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36261902)

  • 121. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.
    Cunningham KN; Rosmarin D
    Am J Clin Dermatol; 2023 Mar; 24(2):165-186. PubMed ID: 36715849
    [TBL] [Abstract][Full Text] [Related]  

  • 124. JAK inhibitors in the treatment of atopic dermatitis.
    Chovatiya R; Paller AS
    J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Integrating neuronal involvement into the immune and genetic paradigm of vitiligo.
    Al Abadie MS; Gawkrodger DJ
    Clin Exp Dermatol; 2021 Jun; 46(4):646-650. PubMed ID: 33098692
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
    Hwang JR; Driscoll MS
    Ann Pharmacother; 2023 Aug; 57(8):948-955. PubMed ID: 36564903
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Vitiligo: an update on systemic treatments.
    Searle T; Al-Niaimi F; Ali FR
    Clin Exp Dermatol; 2021 Mar; 46(2):248-258. PubMed ID: 33350506
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
    Niu C; Xie H; Aisa HA
    Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Topical pimecrolimus in the treatment of vitiligo.
    Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
    Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature.
    Abdelmaksoud A; Dave DD; Lotti T; Vestita M
    Dermatol Ther; 2019 Sep; 32(5):e13013. PubMed ID: 31265164
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
    Svoboda SA; Johnson N; Phillips M
    Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Trichomegaly induced by topical tacrolimus for the treatment of periorbital vitiligo: A brief report of a new adverse effect.
    Molés-Poveda P; Cowen EW
    Pediatr Dermatol; 2019 Jul; 36(4):e95-e96. PubMed ID: 31070265
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Topical treatment in vitiligo and the potential uses of new drug delivery systems.
    Garg BJ; Saraswat A; Bhatia A; Katare OP
    Indian J Dermatol Venereol Leprol; 2010; 76(3):231-8. PubMed ID: 20445292
    [TBL] [Abstract][Full Text] [Related]  

  • 137. New treatment modalities for vitiligo: focus on topical immunomodulators.
    Kostovic K; Pasic A
    Drugs; 2005; 65(4):447-59. PubMed ID: 15733009
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Biologic and targeted therapeutics in vitiligo.
    Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
    J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
    [TBL] [Abstract][Full Text] [Related]  

  • 139. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review.
    Abduelmula A; Mufti A; Mistry J; Sachdeva M; Beecker J; Prajapati VH; Yeung J
    J Cutan Med Surg; 2023; 27(1):73-75. PubMed ID: 36189927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.